Direct to Confusion: Lessons Learned from Marketing BRCA Testing
- 22 August 2008
- journal article
- research article
- Published by Taylor & Francis in American Journal of Bioethics
- Vol. 8 (6) , 5-8
- https://doi.org/10.1080/15265160802248179
Abstract
Myriad Genetics holds a patent on testing for the hereditary breast and ovarian cancer genes, BRCA1 and BRCA2, and therefore has a forced monopoly on this critical genetic test. Myriad launched a Direct-to-Consumer (DTC) marketing campaign in the Northeast United States in September 2007 and plans to expand that campaign to Florida and Texas in 2008. The ethics of Myriad's patent, forced monopoly and DTC campaign will be reviewed, as well as the impact of this situation on patient access and care, physician liability, and the future of DTC campaigns for genetic testing.Keywords
This publication has 19 references indexed in Scilit:
- ‘Be ready against cancer, now’: direct-to-consumer advertising for genetic testingNew Genetics and Society, 2006
- The European Opposition Against the BRCA Gene Patents*Familial Cancer, 2006
- Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physiciansJournal of Medical Genetics, 2005
- Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study GroupJournal of Clinical Oncology, 2004
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2Science, 2003
- Direct-to-Consumer Marketing of Genetic Tests for Cancer: Buyer BewareJournal of Clinical Oncology, 2003
- IMPACT OF GENE PATENTS ON THE COST-EFFECTIVE DELIVERY OF CARE: THE CASE OF BRCA1 GENETIC TESTINGInternational Journal of Technology Assessment in Health Care, 2003
- Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13Science, 1994
- Risks of cancer in BRCA1-mutation carriersThe Lancet, 1994
- Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21Science, 1990